The United Kingdom and the United States have concluded a significant bilateral deal that will keep zero levies on British pharmaceutical shipments being sold in the US market.
Key Provisions of the Accord
In exchange for the tariff guarantee, the UK has pledged to boost spending on medicines through the National Health Service (NHS). This pledge secures that tariffs on these key exports will remain at zero for a timeframe of the next three years.
This deal comes after earlier threats to dramatically increase duties on patented pharmaceutical products, with increases discussed reaching 100%.
"This deal between the UK bolsters the international landscape for cutting-edge drugs and establishes long-overdue equity to American-British drug exports," a statement said.
Economic Impact
Medicines are one of the Britain's biggest export categories to the America, which is clearly the primary buyer for major British pharmaceutical firms.
Trade data indicate that in the year leading up to last September, the UK sold pharmaceutical products worth £11.1bn to the US. This amount accounted for nearly one-fifth of total UK exports in that timeframe.
"This deal secures jobs, stimulates capital expenditure and facilitates the UK to become a worldwide center for biotech and pharma," a government official stated.
Key British Pledges
The agreement involves several key pledges from the British government:
- Price Threshold Increase: The UK will raise the cost ceiling at which it judges new therapies to be too expensive by a quarter.
- Higher Drug Budget: There is a target to increase overall public funding on treatments from 0.3 percent of GDP to 0.6% over the following ten-year period.
- Rebate Cap: The amount pharmaceutical firms must pay back to the NHS to control costs will be capped at 15%. Previously, rebates topped 20%.
Recent Tensions
The deal takes place against a long-running row between the sector and the UK government over medicine costs and regulatory access.
This friction were intensified by claims that American consumers were paying several times more for the same drugs than people in the UK and Europe.
Recently, several large manufacturing plans in the UK have been halted or cancelled, while major investments have been pledged toward US facilities.
One official stated that the NHS needed to spend more on drugs, noting that its expenditure on drugs had declined as a share of its resources over the past decade.
